标题
BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
作者
关键词
-
出版物
MOLECULES
Volume 28, Issue 7, Pages 3043
出版商
MDPI AG
发表日期
2023-03-30
DOI
10.3390/molecules28073043
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Recent Advances in Dual BRD4‐Kinase Inhibitors Based on Polypharmacology
- (2022) Li Chen et al. ChemMedChem
- BET bromodomain inhibitors
- (2022) Martin P. Schwalm et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation‐induced profibrotic fibroblast responses
- (2022) Chun‐Shan Liu et al. INTERNATIONAL JOURNAL OF CANCER
- Clinical considerations for the design of PROTACs in cancer
- (2022) Cristina Nieto-Jiménez et al. Molecular Cancer
- Histone post-translational modifications — cause and consequence of genome function
- (2022) Gonzalo Millán-Zambrano et al. NATURE REVIEWS GENETICS
- A Comprehensive Review of BET Protein Biochemistry, Physiology, and Pathological Roles
- (2022) Hafiz Akbar Ali et al. Frontiers in Pharmacology
- Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
- (2022) Rahul Aggarwal et al. CLINICAL CANCER RESEARCH
- BRD4 and MYC : power couple in transcription and disease
- (2022) Aparna Kotekar et al. FEBS Journal
- PROTACs for BRDs proteins in cancer therapy: a review
- (2022) Chao Wang et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity
- (2022) Xianghong Guan et al. JOURNAL OF MEDICINAL CHEMISTRY
- BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
- (2022) Mengjun Zhong et al. Cell Death & Disease
- NUT Carcinoma—An Underdiagnosed Malignancy
- (2022) Ulrich M. Lauer et al. Frontiers in Oncology
- A comprehensive review of BET-targeting PROTACs for cancer therapy
- (2022) Xiao-Li Zhou et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Design and development of a novel series of oral bivalent BET inhibitors with potent anticancer activities
- (2022) Menglan Luo et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
- (2022) Aqu Alu et al. Journal of Hematology & Oncology
- Co-Encapsulation of Paclitaxel and JQ1 in Zein Nanoparticles as Potential Innovative Nanomedicine
- (2022) Marilena Celano et al. Micromachines
- A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
- (2022) Mark A. Dawson et al. CLINICAL CANCER RESEARCH
- PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery
- (2022) Nicolas Guedeney et al. DRUG DISCOVERY TODAY
- The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma
- (2022) Si-Qi Jia et al. Journal of Immunology Research
- Modulation of BRD4 in HIV epigenetic regulation: implications for finding an HIV cure
- (2021) Edrous Alamer et al. Retrovirology
- Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials
- (2021) Yanli Sun et al. Frontiers in Pharmacology
- A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome
- (2021) Gail J. Roboz et al. LEUKEMIA & LYMPHOMA
- Discovery and characterization of bromodomain 2–specific inhibitors of BRDT
- (2021) Zhifeng Yu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting the acetylation signaling pathway in cancer therapy
- (2021) Fabin Dang et al. SEMINARS IN CANCER BIOLOGY
- A common binding motif in the ET domain of BRD3 forms polymorphic structural interfaces with host and viral proteins
- (2021) Sriram Aiyer et al. STRUCTURE
- Understanding the Function of Mammalian Sirtuins and Protein Lysine Acylation
- (2021) Miao Wang et al. Annual Review of Biochemistry
- Achieving clinical success with BET inhibitors as anti-cancer agents
- (2021) Tatiana Shorstova et al. BRITISH JOURNAL OF CANCER
- A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia
- (2021) Gautam Borthakur et al. CANCER
- BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells
- (2021) Xiao Zhou et al. ONCOLOGY REPORTS
- Strategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges
- (2021) Kristine E. Yoder et al. Frontiers in Molecular Biosciences
- Aptamer‐PROTAC Conjugates (APCs) for Tumor‐Specific Targeting in Breast Cancer
- (2021) Shipeng He et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
- (2021) Renumathy Dhanasekaran et al. Nature Reviews Clinical Oncology
- Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer
- (2021) Wenyu Wang et al. Nature Communications
- E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points
- (2021) Aleša Bricelj et al. Frontiers in Chemistry
- Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation
- (2021) Ming He et al. Frontiers in Cell and Developmental Biology
- Role of BET Proteins in Inflammation and CNS Diseases
- (2021) Lei Liu et al. Frontiers in Molecular Biosciences
- BRD4 in physiology and pathology: ‘‘BET’’ on its partners
- (2021) Yin Liang et al. BIOESSAYS
- Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I / II open‐label, dose escalation study
- (2021) Sophie Cousin et al. INTERNATIONAL JOURNAL OF CANCER
- BET Proteins as Attractive Targets for Cancer Therapeutics
- (2021) Joanna Sarnik et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The intrinsic kinase activity of BRD4 spans its BD2-B-BID domains
- (2021) Jocelyn D. Weissman et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Selectively targeting individual bromodomain: Drug discovery and molecular mechanisms
- (2021) Qianqian Wang et al. PHARMACOLOGICAL RESEARCH
- Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
- (2020) George M. Burslem et al. CELL
- Jumonji domain‐containing protein 6 protein and its role in cancer
- (2020) Jing Yang et al. CELL PROLIFERATION
- Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
- (2020) Emily J. Faivre et al. NATURE
- Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
- (2020) Marı́a Maneiro et al. ACS Chemical Biology
- Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms
- (2020) Qunying Jia et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- The therapeutic potential of BRD4 in cardiovascular disease
- (2020) Shigang Lin et al. HYPERTENSION RESEARCH
- Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain
- (2020) George S. Sheppard et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation
- (2020) Zhiqing Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective targeting of BD1 and BD2 of the BET proteins in cancer and immuno-inflammation
- (2020) Omer Gilan et al. SCIENCE
- Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction
- (2020) Mingzhu Yin et al. Nature Communications
- BET Inhibitors Synergize with Carfilzomib to Induce Cell Death in Cancer Cells via Impairing Nrf1 Transcriptional Activity and Exacerbating the Unfolded Protein Response
- (2020) Janakiram R. Vangala et al. Biomolecules
- Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma
- (2020) V. Moreno et al. ANNALS OF ONCOLOGY
- Bromodomain-selective BET inhibitors are potent antitumor agents against MYC-driven pediatric cancer
- (2020) P. Jake Slavish et al. CANCER RESEARCH
- BRD4 regulates key transcription factors that drive epithelial–mesenchymal transition in castration-resistant prostate cancer
- (2020) Jordan S. Shafran et al. PROSTATE CANCER AND PROSTATIC DISEASES
- A Bromodomain-Containing Protein 4 (BRD4) Inhibitor Suppresses Angiogenesis by Regulating AP-1 Expression
- (2020) Zijun Zhou et al. Frontiers in Pharmacology
- A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity
- (2020) Adam M. Burgoyne et al. Cell Discovery
- An Adaptive Physiologically Based Pharmacokinetic–Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers
- (2020) Kylie Riddell et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma
- (2020) Geoffrey I. Shapiro et al. BRITISH JOURNAL OF CANCER
- FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
- (2020) Vanessa E. Kennedy et al. Frontiers in Oncology
- NUT carcinoma in a nutshell: A diagnosis to be considered more frequently
- (2019) Thomas Albrecht et al. PATHOLOGY RESEARCH AND PRACTICE
- BRD4 directs hematopoietic stem cell development and modulates macrophage inflammatory responses
- (2019) Anup Dey et al. EMBO JOURNAL
- Structural Insights into BET Client Recognition of Endometrial and Prostate Cancer-Associated SPOP Mutants
- (2019) Michael Sebastian Ostertag et al. JOURNAL OF MOLECULAR BIOLOGY
- Acquired Resistance to BET-PROTACs(Proteolysis Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 ligase Complexes
- (2019) Lu Zhang et al. MOLECULAR CANCER THERAPEUTICS
- A chemical toolbox for the study of bromodomains and epigenetic signaling
- (2019) Qin Wu et al. Nature Communications
- Chemical Proteomic Profiling of Bromodomains Enables the Wide-Spectrum Evaluation of Bromodomain Inhibitors in Living Cells
- (2019) Xin Li et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Molecular mechanisms of cereblon-based drugs
- (2019) Tomoko Asatsuma-Okumura et al. PHARMACOLOGY & THERAPEUTICS
- JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma
- (2019) Matthew Wong et al. Nature Communications
- Degradation of proteins by PROTACs and other strategies
- (2019) Yang Wang et al. Acta Pharmaceutica Sinica B
- Light-Induced Protein Degradation with Photocaged PROTACs
- (2019) Gang Xue et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Bromodomain biology and drug discovery
- (2019) Nilesh Zaware et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo
- (2018) Kun Xu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells
- (2018) Mark Wroblewski et al. HAEMATOLOGICA
- The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators
- (2018) Dorothy C. C. Wai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
- (2018) Jeremy Lewin et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
- (2018) Chong Qin et al. JOURNAL OF MEDICINAL CHEMISTRY
- BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition
- (2018) Guillaume P. Andrieu et al. MOLECULAR CANCER RESEARCH
- Plasticity in binding confers selectivity in ligand-induced protein degradation
- (2018) Radosław P. Nowak et al. Nature Chemical Biology
- Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
- (2018) Sara Bolin et al. ONCOGENE
- Coactivator condensation at super-enhancers links phase separation and gene control
- (2018) Benjamin R. Sabari et al. SCIENCE
- The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine
- (2018) Fang Xie et al. Scientific Reports
- BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells
- (2018) Mark Wroblewski et al. HAEMATOLOGICA
- MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers
- (2018) Anastasia Wyce et al. Oncogenesis
- Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy
- (2018) Subhankar Biswas et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma
- (2018) Jixiang Shi et al. MOLECULAR PHARMACEUTICS
- Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling
- (2018) Amanda Balboni Iniguez et al. CANCER CELL
- BRD4 and Cancer: going beyond transcriptional regulation
- (2018) Benedetta Donati et al. Molecular Cancer
- NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment
- (2018) Christopher A. French PATHOLOGY INTERNATIONAL
- The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
- (2017) Tania Díaz et al. HAEMATOLOGICA
- Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics
- (2017) Stuart W. Ember et al. MOLECULAR CANCER THERAPEUTICS
- Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
- (2017) Xiangpeng Dai et al. NATURE MEDICINE
- Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation
- (2017) Pingzhao Zhang et al. NATURE MEDICINE
- Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors
- (2017) Hana Janouskova et al. NATURE MEDICINE
- Functions of bromodomain-containing proteins and their roles in homeostasis and cancer
- (2017) Takao Fujisawa et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner
- (2017) Vivek Kumar Mishra et al. NUCLEIC ACIDS RESEARCH
- Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis
- (2017) Forest H. Andrews et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- VEGF amplifies transcription through ETS1 acetylation to enable angiogenesis
- (2017) Jiahuan Chen et al. Nature Communications
- BET Proteins as Targets for Anticancer Treatment
- (2017) Anastasios Stathis et al. Cancer Discovery
- Structural Mechanism of the Oxygenase JMJD6 Recognition by the Extraterminal (ET) Domain of BRD4
- (2017) Tsuyoshi Konuma et al. Scientific Reports
- The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
- (2017) Tania Díaz et al. HAEMATOLOGICA
- Targeting myeloid cells in the tumor sustaining microenvironment
- (2017) Jonathan Schupp et al. CELLULAR IMMUNOLOGY
- Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer
- (2016) U.A. Matulonis et al. ANNALS OF ONCOLOGY
- AMPK–ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells
- (2016) Ji Eun Jang et al. CLINICAL CANCER RESEARCH
- The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects
- (2016) J. Shahbazi et al. CLINICAL CANCER RESEARCH
- Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts
- (2016) Ramiro Vázquez et al. INTERNATIONAL JOURNAL OF CANCER
- The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo
- (2016) Sina Jostes et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective
- (2016) Luca Carlino et al. JOURNAL OF MEDICINAL CHEMISTRY
- Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)
- (2016) Robert H. Bradbury et al. JOURNAL OF MEDICINAL CHEMISTRY
- AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
- (2016) G. W. Rhyasen et al. MOLECULAR CANCER THERAPEUTICS
- Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
- (2016) Shaokun Shu et al. NATURE
- Potent and selective bivalent inhibitors of BET bromodomains
- (2016) Michael J Waring et al. Nature Chemical Biology
- Design and characterization of bivalent BET inhibitors
- (2016) Minoru Tanaka et al. Nature Chemical Biology
- Structure of the Brd4 ET domain bound to a C-terminal motif from γ-retroviral integrases reveals a conserved mechanism of interaction
- (2016) Brandon L. Crowe et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural Mechanism of Transcriptional Regulator NSD3 Recognition by the ET Domain of BRD4
- (2016) Qiang Zhang et al. STRUCTURE
- Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
- (2016) A. Stathis et al. Cancer Discovery
- Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
- (2016) Alison M. Kurimchak et al. Cell Reports
- The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis
- (2016) Olga Aprelikova et al. Clinical Epigenetics
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
- (2016) Sandy Amorim et al. Lancet Haematology
- Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
- (2016) Honorine Lebraud et al. ACS Central Science
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
- (2015) Michael Zengerle et al. ACS Chemical Biology
- Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib
- (2015) B. Sun et al. BLOOD
- Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
- (2015) Elias E. Stratikopoulos et al. CANCER CELL
- Elevated expression of JMJD6 is associated with oral carcinogenesis and maintains cancer stemness properties
- (2015) Chang-Ryul Lee et al. CARCINOGENESIS
- aBETting therapeutic resistance by Wnt signaling
- (2015) Carl G Engelke et al. CELL RESEARCH
- The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
- (2015) M. Boi et al. CLINICAL CANCER RESEARCH
- Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies
- (2015) Elodie Odore et al. CLINICAL PHARMACOKINETICS
- The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains
- (2015) Artyom A. Alekseyenko et al. GENES & DEVELOPMENT
- NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler
- (2015) Chen Shen et al. MOLECULAR CELL
- BET inhibitor resistance emerges from leukaemia stem cells
- (2015) Chun Yew Fong et al. NATURE
- Prime time for PROTACs
- (2015) Raymond J Deshaies Nature Chemical Biology
- What are super-enhancers?
- (2015) Sebastian Pott et al. NATURE GENETICS
- Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
- (2015) Pawel K Mazur et al. NATURE MEDICINE
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
- (2015) Lei-lei Fu et al. Oncotarget
- Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling
- (2015) Anja Heinemann et al. Oncotarget
- BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
- (2015) Marie-Magdelaine Coudé et al. Oncotarget
- BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells
- (2015) Emma K Baker et al. Scientific Reports
- GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
- (2015) Krishan Kumar et al. Scientific Reports
- Role of JMJD6 in Breast Tumourigenesis
- (2015) Coralie Poulard et al. PLoS One
- Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors
- (2014) Stuart W. J. Ember et al. ACS Chemical Biology
- SWI/SNF chromatin remodeling complexes and cancer
- (2014) Jaclyn A. Biegel et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS
- The bromodomain: From epigenome reader to druggable target
- (2014) Roberto Sanchez et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Comparative drug screening in NUT midline carcinoma
- (2014) A H Beesley et al. BRITISH JOURNAL OF CANCER
- Small Molecule Control of Chromatin Remodeling
- (2014) Aidan Finley et al. CHEMISTRY & BIOLOGY
- Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma
- (2014) Dhong Hyun Lee et al. INTERNATIONAL JOURNAL OF CANCER
- Mechanistic Analysis of the Role of Bromodomain-containing Protein 4 (BRD4) in BRD4-NUT Oncoprotein-induced Transcriptional Activation
- (2014) Ranran Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells
- (2014) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
- (2014) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
- (2014) Pietro Ciceri et al. Nature Chemical Biology
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- Molecular mechanisms of retroviral integration site selection
- (2014) Mamuka Kvaratskhelia et al. NUCLEIC ACIDS RESEARCH
- Bimodal high-affinity association of Brd4 with murine leukemia virus integrase and mononucleosomes
- (2014) Ross C. Larue et al. NUCLEIC ACIDS RESEARCH
- BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma
- (2014) Joydeep Bhadury et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
- (2014) E. Seto et al. Cold Spring Harbor Perspectives in Biology
- NSD3-NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism
- (2014) C. A. French et al. Cancer Discovery
- Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
- (2014) Jessica E. Bolden et al. Cell Reports
- JMJD6 Promotes Colon Carcinogenesis through Negative Regulation of p53 by Hydroxylation
- (2014) Feng Wang et al. PLOS BIOLOGY
- Regulation of chromatin structure via histone post-translational modification and the link to carcinogenesis
- (2013) Laura L. Thompson et al. CANCER AND METASTASIS REVIEWS
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- Brd4 and JMJD6-Associated Anti-Pause Enhancers in Regulation of Transcriptional Pause Release
- (2013) Wen Liu et al. CELL
- Synthesis and Cancer Stem Cell-Based Activity of Substituted 5-Morpholino-7H-thieno[3,2-b]pyran-7-ones Designed as Next Generation PI3K Inhibitors
- (2013) Guillermo A. Morales et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bromo- and Extraterminal Domain Chromatin Regulators Serve as Cofactors for Murine Leukemia Virus Integration
- (2013) Saumya Shree Gupta et al. JOURNAL OF VIROLOGY
- BET proteins promote efficient murine leukemia virus integration at transcription start sites
- (2013) A. Sharma et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- High expression of JMJD6 predicts unfavorable survival in lung adenocarcinoma
- (2013) Ji Zhang et al. TUMOR BIOLOGY
- Small-Molecule Inhibition of BRDT for Male Contraception
- (2012) Martin M. Matzuk et al. CELL
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
- (2012) Panagis Filippakopoulos et al. CELL
- Cross-talk Among RNA Polymerase II Kinases Modulates C-terminal Domain Phosphorylation
- (2012) Ballachanda N. Devaiah et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Challenges in Vector and Trial Design Using Retroviral Vectors for Long-Term Gene Correction in Hematopoietic Stem Cell Gene Therapy
- (2012) Jacqueline Corrigan-Curay et al. MOLECULAR THERAPY
- Place your BETs: the therapeutic potential of bromodomains
- (2012) R.K. Prinjha et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Pathogenesis of NUT Midline Carcinoma
- (2011) Christopher A. French Annual Review of Pathology-Mechanisms of Disease
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Structural Basis and Specificity of Acetylated Transcription Factor GATA1 Recognition by BET Family Bromodomain Protein Brd3
- (2011) R. Gamsjaeger et al. MOLECULAR AND CELLULAR BIOLOGY
- The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3
- (2011) S. Rahman et al. MOLECULAR AND CELLULAR BIOLOGY
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation
- (2010) P. Perez-Galan et al. BLOOD
- NUT midline carcinoma
- (2010) Christopher Alexander French CANCER GENETICS AND CYTOGENETICS
- Suppression of inflammation by a synthetic histone mimic
- (2010) Edwige Nicodeme et al. NATURE
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- The Biology of Chromatin Remodeling Complexes
- (2009) Cedric R. Clapier et al. Annual Review of Biochemistry
- Structures of the Dual Bromodomains of the P-TEFb-activating Protein Brd4 at Atomic Resolution
- (2009) Friederike Vollmuth et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Brd4 Marks Select Genes on Mitotic Chromatin and Directs Postmitotic Transcription
- (2009) Anup Dey et al. MOLECULAR BIOLOGY OF THE CELL
- Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation
- (2009) P. Hydbring et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
- (2009) C. Choudhary et al. SCIENCE
- Solution structure of the extraterminal domain of the bromodomain-containing protein BRD4
- (2008) Yi-Jan Lin et al. PROTEIN SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation